12-Hydroxyeicosapentaenoic acid inhibits foam cell formation and ameliorates high-fat diet-induced pathology of atherosclerosis in mice.
Animals
Atherosclerosis
/ blood
Cell Differentiation
Diet, High-Fat
/ adverse effects
Dietary Supplements
Disease Models, Animal
Eicosapentaenoic Acid
/ administration & dosage
Foam Cells
/ metabolism
Humans
Linseed Oil
/ administration & dosage
Male
Mice
Obesity
/ complications
PPAR gamma
/ metabolism
Soybean Oil
/ administration & dosage
Weight Gain
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 05 2021
17 05 2021
Historique:
received:
28
12
2020
accepted:
26
04
2021
entrez:
18
5
2021
pubmed:
19
5
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Atherosclerosis is a chronic inflammatory disease associated with macrophage aggregate and transformation into foam cells. In this study, we sought to investigate the impact of dietary intake of ω3 fatty acid on the development of atherosclerosis, and demonstrate the mechanism of action by identifying anti-inflammatory lipid metabolite. Mice were exposed to a high-fat diet (HFD) supplemented with either conventional soybean oil or α-linolenic acid-rich linseed oil. We found that as mice became obese they also showed increased pulsatility and resistive indexes in the common carotid artery. In sharp contrast, the addition of linseed oil to the HFD improved pulsatility and resistive indexes without affecting weight gain. Histological analysis revealed that dietary linseed oil inhibited foam cell formation in the aortic valve. Lipidomic analysis demonstrated a particularly marked increase in the eicosapentaenoic acid-derived metabolite 12-hydroxyeicosapentaenoic acid (12-HEPE) in the serum from mice fed with linseed oil. When we gave 12-HEPE to mice with HFD, the pulsatility and resistive indexes was improved. Indeed, 12-HEPE inhibited the foamy transformation of macrophages in a peroxisome proliferator-activated receptor (PPAR)γ-dependent manner. These results demonstrate that the 12-HEPE-PPARγ axis ameliorates the pathogenesis of atherosclerosis by inhibiting foam cell formation.
Identifiants
pubmed: 34001916
doi: 10.1038/s41598-021-89707-1
pii: 10.1038/s41598-021-89707-1
pmc: PMC8129127
doi:
Substances chimiques
PPAR gamma
0
Pparg protein, mouse
0
12-hydroxy-5,8,10,14,17-eicospentaenoic acid
74838-73-6
Soybean Oil
8001-22-7
Linseed Oil
8001-26-1
Eicosapentaenoic Acid
AAN7QOV9EA
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10426Références
Diabetes. 2001 Sep;50(9):2094-9
pubmed: 11522676
Nutrients. 2019 Nov 22;11(12):
pubmed: 31766714
J Atheroscler Thromb. 2003;10(2):63-71
pubmed: 12740479
J Cell Mol Med. 2020 Oct;24(20):11729-11741
pubmed: 32851768
Int Immunol. 2019 Aug 23;31(9):569-577
pubmed: 30722032
Circulation. 1999 Dec 21-28;100(25):2473-6
pubmed: 10604883
J Lipid Res. 2014 May;55(5):895-904
pubmed: 24668940
Circulation. 2006 Feb 14;113(6):898-918
pubmed: 16380542
J Clin Invest. 2000 Aug;106(4):523-31
pubmed: 10953027
Cell Metab. 2007 Aug;6(2):96-8
pubmed: 17681144
Lancet. 1978 Jul 15;2(8081):117-9
pubmed: 78322
Basic Res Cardiol. 2020 Nov 30;115(6):73
pubmed: 33258000
Int J Clin Exp Pathol. 2015 Sep 01;8(9):10854-60
pubmed: 26617799
Br J Pharmacol. 2017 Oct;174(20):3496-3513
pubmed: 28063251
Int Immunol. 2019 Aug 23;31(9):559-567
pubmed: 30772915
Postepy Hig Med Dosw (Online). 2010 Mar 17;64:115-32
pubmed: 20354260
FASEB J. 1992 May;6(8):2530-6
pubmed: 1592205
FASEB Bioadv. 2019 Dec 24;2(1):59-71
pubmed: 32123857
J Hypertens. 2005 Oct;23(10):1905-11
pubmed: 16148615
Cell Metab. 2007 Aug;6(2):137-43
pubmed: 17681149
Scand J Clin Lab Invest Suppl. 1982;161:7-13
pubmed: 6293041
Front Cardiovasc Med. 2018 Sep 25;5:130
pubmed: 30320124
Crit Care Med. 2000 Jul;28(7):2600-7
pubmed: 10921602
Allergy. 2020 Aug;75(8):1939-1955
pubmed: 32027039
FASEB J. 2008 Oct;22(10):3595-606
pubmed: 18559988
Cell. 1998 Apr 17;93(2):241-52
pubmed: 9568716
Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1419-23
pubmed: 19696407
J Allergy Clin Immunol. 2018 Aug;142(2):470-484.e12
pubmed: 29288079
Annu Rev Immunol. 2004;22:129-56
pubmed: 15032576
N Engl J Med. 1999 Oct 7;341(15):1097-105
pubmed: 10511607
Mol Nutr Food Res. 2014 Mar;58(3):580-90
pubmed: 24311515
Cell Death Dis. 2013 Mar 21;4:e551
pubmed: 23519120
Circulation. 2013 Mar 19;127(11):1209-18, e1-16
pubmed: 23401155
Am J Clin Nutr. 1980 Dec;33(12):2657-61
pubmed: 7435433
Cell. 2001 Feb 23;104(4):503-16
pubmed: 11239408
J Leukoc Biol. 2010 Jul;88(1):33-9
pubmed: 20360405
J Biol Chem. 2003 Jan 24;278(4):2461-8
pubmed: 12431986
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5034-9
pubmed: 23479619
Korean Circ J. 2014 Nov;44(6):406-14
pubmed: 25469143
Nat Immunol. 2005 Dec;6(12):1182-90
pubmed: 16369557
Front Endocrinol (Lausanne). 2021 Feb 26;12:624112
pubmed: 33716977
FASEB J. 2014 Sep;28(9):4036-43
pubmed: 24891522
Arterioscler Thromb Vasc Biol. 2012 May;32(5):1104-15
pubmed: 22383700
Cell Rep. 2018 Apr 24;23(4):974-982
pubmed: 29694905
Lipids Health Dis. 2018 Jul 31;17(1):182
pubmed: 30064511
J Clin Invest. 2018 Jul 2;128(7):2657-2669
pubmed: 29757195
Diabetes. 2009 Nov;58(11):2574-82
pubmed: 19690061
EBioMedicine. 2016 Jul;9:61-76
pubmed: 27374313
Immunity. 2012 May 25;36(5):834-46
pubmed: 22503541
Biomed Pharmacother. 2020 Sep;129:110426
pubmed: 32574973
Mucosal Immunol. 2019 Sep;12(5):1082-1091
pubmed: 31142830
J Clin Invest. 2001 May;107(10):1255-62
pubmed: 11375415
PLoS One. 2010 Jan 25;5(1):e8852
pubmed: 20111605
Sci Rep. 2015 Jun 11;5:9750
pubmed: 26065911
Circulation. 2001 Feb 27;103(8):1057-63
pubmed: 11222466
J Clin Invest. 2004 Dec;114(11):1564-76
pubmed: 15578089
J Neuroimaging. 2020 Mar;30(2):233-239
pubmed: 31889363
Nat Med. 2001 Jan;7(1):53-8
pubmed: 11135616
Immunopharmacol Immunotoxicol. 2012 Jun;34(3):470-6
pubmed: 22047042
J Immunol. 2010 Nov 1;185(9):5619-27
pubmed: 20935201